Skip to content

The safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10 in healthy adults

The safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10 in healthy adults - Safety evaluation of excessive intake of Saccharomyces cerevisiae SM-10

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022649
Enrollment
10
Registered
2016-06-07
Start date
2016-06-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

SM-10 supplements are ingested for 4 consecutive weeks at 3,000 mg.

Sponsors

TTC CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Healthy males and females at the ages of 20 to 64

Exclusion criteria

Exclusion criteria: 1. Subjects who routinely use health food containing S-adenosyl methionine 2. Subjects having a current or past history of serious diseases such as diabetes, hepatic or renal disorder, or cardiovascular disease 3. Subjects having possibilities for emerging allergy related to the study 4. Subjects having possibilities for emerging allergy related to the study 5. Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination 6. Subjects who have participated in other clinical studies within the last one month prior to the current study or are planned to participate in other studies after obtaining informed consent for the current study 7. Subjects who intend to become pregnant or lactating 8. Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire 9. Subjects who are judged as unsuitable for this study by physician

Design outcomes

Primary

MeasureTime frame
Hematologic test Blood biochemistry test Urine test Blood pressure/pulsation Weight/body mass index Medical Interview Adverse event

Countries

Japan

Contacts

Public Contacthiroko onoda, tomohiro utsue, sayuri fujita

Horus Co., Ltd. Academic Planning Department

gakujutu.mail@horus-jnl.co.jp03-5328-9331

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026